Full Access
A New Ergoline Derivative, LEK-8829, as a Potential New Antipsychotic Drug
Igor Krisch,
Rudolf Rucman,
Anton Lavric,
Magdalena Ocvirk,
Breda Bole-Vunduk,
Corresponding Author
Igor Krisch
Departments of Pharmacology, Ljubljana, Slovenia.
Address correspondence and reprint requests to: Dr. Igor Krisch, Department of Pharmacology, Research & Development, LEK Pharmaceutical and Chemical Company, Verovskova 57, P. O. Box 81, 1107 Ljubljana, Slovenia. Fax:386-61-168-3052.Search for more papers by this authorRudolf Rucman
Departments of Organic Chemistry, Ljubljana, Slovenia.
Search for more papers by this authorAnton Lavric
Toxicology, Research & Development, LEK Pharmaceutical and Chemical Company, Ljubljana, Slovenia.
Search for more papers by this authorMagdalena Ocvirk
Departments of Pharmacology, Ljubljana, Slovenia.
Search for more papers by this authorBreda Bole-Vunduk
Departments of Pharmacology, Ljubljana, Slovenia.
Search for more papers by this authorIgor Krisch,
Rudolf Rucman,
Anton Lavric,
Magdalena Ocvirk,
Breda Bole-Vunduk,
Corresponding Author
Igor Krisch
Departments of Pharmacology, Ljubljana, Slovenia.
Address correspondence and reprint requests to: Dr. Igor Krisch, Department of Pharmacology, Research & Development, LEK Pharmaceutical and Chemical Company, Verovskova 57, P. O. Box 81, 1107 Ljubljana, Slovenia. Fax:386-61-168-3052.Search for more papers by this authorRudolf Rucman
Departments of Organic Chemistry, Ljubljana, Slovenia.
Search for more papers by this authorAnton Lavric
Toxicology, Research & Development, LEK Pharmaceutical and Chemical Company, Ljubljana, Slovenia.
Search for more papers by this authorMagdalena Ocvirk
Departments of Pharmacology, Ljubljana, Slovenia.
Search for more papers by this authorBreda Bole-Vunduk
Departments of Pharmacology, Ljubljana, Slovenia.
Search for more papers by this author
References
- 1 Ahlenius S. Antipsychotic-like properties of the 5-HT1A agonist 8-OH-DPAT in the rat. Pharmacol Toxicol 1989; 64: 3–5.
- 2 Apperley E, Humphrey PPA, Levy GP. Receptors for 5-hydroxytryptamine and noradrenaline in rabbit isolated ear artery and aorta. Br J Pharmacol 1976; 58: 211–221.
- 3 Balant-Gorgia AE, Balant LP, Andreoli A. Pharmacokinetic optimisation of the treatment of psychosis. Clin Pharmacokinet 1993; 25: 217–236.
- 4 Breier A. Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res 1995; 14: 187–202.
- 5 Cook L, Tarn SW, Rohrbach KW. Dup 734 l-(cyclopropylmethyl)-4-(2′4″-fluorophenyl)-2′-oxoethyl)piperidine HBr, a potential antipsyhotic agent: Preclinical behavioral effects. J Pharmacol Exp Ther 1992; 263: 1159–1166.
- 6 Costall B, Naylor RJ, Nohira V. Hyperactivity response to apomorphine and amphetamine in the mouse: The importance of the nucleus accumbens and caudate-putamen. J Pharm Pharmacol 1979; 31: 259–261.
- 7 Coward DM. General pharmacology of clozapine. Br J Psychiat (Suppl 17) 1992; 160: 5–11.
- 8 Gerlach J. New antipsychotics: Classification, efficacy, and adverse effects. Schizophr Bull 1991; 17: 289–309.
- 9 Green AR, Heal DJ. The effects of drugs on serotonin-mediated behavioural models. In: RA Green, ed. Neuropharmacology of Serotonin. Oxford : Oxford University Press, 1985; 326–365.
- 10 Hicks PB. The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci 1990; 47: 1609–1615.
- 11 Hirose A, Kato T, Ohno Y, et al. Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions. Jpn J Pharmacol 1990; 53: 321–329.
- 12 Hrib NJ, Jurcak JG, Huger FP, Errico CL, Dunn RW. Synthesis and biological evaluation of a series of substituted N-alkoxyimides and -amides as potential atypical antipsychotic agents. J Med Chem 1991; 34: 1068–1072.
- 13 Kahn RS, Davis KL. New developments in dopamine and schizophrenia. In: FE Bloom, DJ Kupfer, eds. Psychopharmacology: The fourth generation of progress. New York : Raven Press, 1995; 1193–1203.
- 14 Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993; 19: 287–302.
- 15
Krisch I,
Bole-Vunduk B,
Rucman R.
Comparative 5-HT2A receptor and α1-adrenoceptor antagonistic activity of an ergoline LEK-8829 and its degradation product LEK-1814 in rabbit isolated aorta.
Pharmacol Res (Suppl)
1995; 31: 248.
10.1016/1043-6618(95)87250-7 Google Scholar
- 16 Krisch I, Budihna MV, Rucman R. Structure-activity study of some newly synthesized ergoline derivatives on 5-HT2 receptors and α-adrenoceptors in rabbit isolated aorta. Pharmacology 1992; 45: 195–208.
- 17 Krisch I, Bole-Vunduk B, Pepelnak M, et al. Pharmacological studies with two new ergoline derivatives, the potential antipsychotics LEK-8829 and LEK-8841. J Pharmacol Exp Ther 1994; 271: 343–352.
- 18 Kuroita T, Ikebe T, Murakami S, Takehara S, Kawakita T. N-(2-pyrrolidinylmethyl)benzoxazine-8-car-boxamides exhibiting high affinities for all of D2, 5-HT1A, and 5-HT2 receptors. Bioorg Med Chem Lett 1995; 5: 1245–1250.
- 19
Lavric A,
Tibaut D,
Culjak K,
Nemec M.
Subchronic toxicity of substance LEK-8829.
Toxicol Lett (Suppl 1) 1995; 78: 52.
10.1016/0378-4274(95)94823-Y Google Scholar
- 20 Leysen JE, Janssen PMF, Schotte A, Luyten WHML, Megens AAHP. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: Role of 5-HT2 receptors. Psychopharmacology (Suppl) 1993; 112: S40–54.
- 21 Lippmann W, Pugsley TA. Effects of 3,4-dihydro-lH-l,4-oxazino [4,3-a] indoles, potential antidepressants, on biogenic amine uptake mechanisms and related activities. Arch Int Pharmacodyn Ther 1977; 227: 324–342.
- 22 Lowe JA III, Segger TF, Nagel AA, et al. 1-naphthylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem 1991; 34: 1860–1866.
- 23 Megens AAHP, Awouters FHL, Meert TF, Schellekens KHL, Niemegeers CJE, Janssen PAJ. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79 598). J Pharmacol Exp Ther 1992; 260: 146–159.
- 24 Megens AAHP, Awouters FHL, Schotte A, et al. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology 1994; 114: 9–23.
- 25 Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2, and serotonin2 pKi values. J Pharmacol Exp Ther 1989; 251: 238–246.
- 26 Meltzer HY. The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiat (Suppl 17) 1992; 160: 22–29.
- 27 Meltzer HY, Gudelsky GA. Dopaminergic and serotonergic effects of clozapine. Arzneimittelforschung 1992; 42: 268–272.
- 28 Meltzer HY, Lee MA, Ranjan R. Recent advances in the pharmacotherapy of schizophrenia. Acta Psychiatr Scand (Suppl 384) 1994; 90: 95–101.
- 29 Millan MJ, Bervoets K, Colpaert FC. 5-hydroxytryptamine (5-HT)1A receptors and the tail-flick response. I. 8-hydroxy-2-(di-n-propylamino) tetralin HBr-induced spontaneous tail-flicks in the rat as an in vivo model of 5-HT1A receptor-mediated activity. J Pharmacol Exp Ther 1991; 256: 973–982.
- 30 Niemegeers CJE, Janssen PAJ. A systematic study of the pharmacological activities of dopamine antagonists. Life Sci 1979; 24: 2201–2216.
- 31 Nishimoto S, Hatta H, Ueshima H, Kagiya T. 3-[4-[l-(6-fluorobenzo[b]thiophen-3-yl-4-piperazinyl]butyl]-2,5,5-trimethyl-4-thiazolidinone: A new atypical antipsychotic agent for the treatment of schizophrenia. J Med Chem 1992; 35: 2712–2715.
- 32 Oka M, Noda Y, Ochi Y, et al. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J Pharmacol Exp Ther 1993; 264: 158–165.
- 33 Peroutka SJ, Snyder SH. Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adren-ergic, and histamine receptors to clinical potency. Am J Psychiatry 1980; 137: 1518–1522.
- 34 Protais P, Costentin J, Schwartz JC. Climbing behavior induced by apomorphine in mice: A simple test for the study of dopamine receptors in striatum. Psychopharmacology 1976; 50: 1–6.
- 35 Rucman R, Bole-Vunduk B, Ocvirk M, Lavric B, Krisch I. Ergoline derivatives of 2-propynylamine, a process for the manufacture thereof and the use thereof for medicaments. U. S. Patent 5,288,724, issued to LEK Pharmaceutical and Chemical Company (Ljubljana, Slovenia), 1994.
- 36 Rucman R, Zlicar M, Bole-Vunduk B, et al. Synthesis, chemical transformations, and pharmacological activity of novel ergolene derivative LEK-8829. AFMC International Medicinal Chemistry Symposium, Tokyo, Japan, 1995, p. 143.
- 37 Seeman P. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 1992; 7: 261–284.
- 38 Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature (Land) 1976; 261: 717–718.
- 39 Seeman P. Atypical neuroleptics: Role of multiple receptors, endogenous dopamine, and receptor linkage. Acta Psychiatr Scand (Suppl 358) 1990; 82: 14–20.
- 40 Sleight AJ, Boess FG, Bourson A, Sibley DR, Monsma FJ. 5-HT6 and 5-HT7 serotonin receptors: Molecular biology and pharmacology. Neurotransmissions 1995; 11: 1–5.
- 41 Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ. (l-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT)2A receptors: Modulation by novel 5-HT2A/2C antagonists, D1 antagonists, and 5-HT1A agonists. J Pharmacol Exp Ther 1995; 273: 101–112.
- 42 Sokoloff P, Martres MP, Giros B, Bouthenet ML, Schwartz, JC. The third dopamine receptor (D3) as a novel target for antipsychotics. Biochem Pharmacol 1992; 43: 659–666.
- 43 Sonsalla PK, Manzino L, Heikkila RE. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. centralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway. J Pharmacol Exp Ther 1988; 247: 180–185.
- 44 Stockmeier CA, Dicarlo JJ, Zhang Y, Thompson P, Meltzer HY. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 1993; 266: 1374–1384.
- 45
Ungerstedt U.
Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigrostriatal dopamine system.
Ada Physiol Scand (Suppl 367) 1971; 83: 69–93.
10.1111/j.1365-201X.1971.tb11000.x Google Scholar
- 46 Yamasaki T, Kojima H, Sakurai T, et al. Pharmacological studies on timiperone, a new neuroleptic drug. Arzneimittelforschung 1981; 31: 701–707.
- 47 Zivin M, Sprah L, Sket D. D1 agonism of LEK-8829, a new ergoline derivative with atypical neuroleptic properties. Annual Meeting of the Austrian Neuroscience Association, Graz, Austria, 1995, p. 61.
- 48 Zivin M, Sprah L, Kos I, Sket D. The D1 receptor mediated effects of LEK-8829 on the rotational behaviour and the c-fos mRNA expression in rats with unilateral dopaminergic denervation. International Conference on Life Sciences, Gozd Martuljek, Slovenia, 1995, p. 177.
